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Abstract
Background: The head and neck/oral squamous cell carcinoma (HNOSCC) is a diverse group of cancers,
which develop from many different anatomic sites and are associated with different risk factors and genetic
characteristics. The oral tongue squamous cell carcinoma (OTSCC) is one of the most common types of
HNOSCC. It is significantly more aggressive than other forms of HNOSCC, in terms of local invasion and
spread. In this study, we aim to identify specific transcriptomic signatures that associated with OTSCC.
Results: Genome-wide transcriptomic profiles were obtained for 53 primary OTSCCs and 22 matching
normal tissues. Genes that exhibit statistically significant differences in expression between OTSCCs and
normal were identified. These include up-regulated genes (MMP1, MMP10, MMP3, MMP12, PTHLH,
INHBA, LAMC2, IL8, KRT17, COL1A2, IFI6, ISG15, PLAU, GREM1, MMP9, IFI44, CXCL1), and down-
regulated genes (KRT4, MAL, CRNN, SCEL, CRISP3, SPINK5, CLCA4, ADH1B, P11, TGM3, RHCG,
PPP1R3C, CEACAM7, HPGD, CFD, ABCA8, CLU, CYP3A5). The expressional difference of IL8 and
MMP9 were further validated by real-time quantitative RT-PCR and immunohistochemistry. The Gene
Ontology analysis suggested a number of altered biological processes in OTSCCs, including enhancements
in phosphate transport, collagen catabolism, I-kappaB kinase/NF-kappaB signaling cascade, extracellular
matrix organization and biogenesis, chemotaxis, as well as suppressions of superoxide release, hydrogen
peroxide metabolism, cellular response to hydrogen peroxide, keratinization, and keratinocyte
differentiation in OTSCCs.
Conclusion: In summary, our study provided a transcriptomic signature for OTSCC that may lead to a
diagnosis or screen tool and provide the foundation for further functional validation of these specific
candidate genes for OTSCC.
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Background
Head and neck/oral squamous cell carcinoma (HNOSCC)
is a complex disease arising in various organs, including
oral cavity, tongue, pharynx, and larynx. Tumors from
these different sites have distinct clinical presentations
and clinical outcomes, and are associated with different
risk factors [1] and genetic characteristics [2]. In this study,
we focused on the oral tongue squamous cell carcinomas
(OTSCC), one of the most common sites for HNOSCCs.
The incidence of OTSCC is actually increasing in young
and middle age groups [3-5]. OTSCC is significantly more
aggressive than other forms of HNOSCCs, with a propen-
sity for rapid local invasion and spread [6].
Cancer cells harbor genetic alterations which are trans-
lated into unique expression patterns. These patterns may
segregate cancer cells from normal tissue of the same ori-
gin and serve as a molecular biomarker. Moreover, expres-
sion pattern changes may occur far earlier than clinical
disease detection. The identification of such patterns has
significant translational values for early detection and
diagnosis, as well as for identifying novel therapeutic tar-
gets. While several recent studies have attempted to iden-
tify expression patterns for HNOSCCs [7-10], to our
knowledge, no study has been devoted to identify the
unique expression pattern for OTSCC. In this study, we
aim to identify the specific transcriptomic/expression pat-
terns that associated with OTSCC.
Results and discussion
Genome-wide gene expression profiles were obtained on
53 OTSCC samples and 22 normal matching samples.
Principal Component Analysis (PCA) was performed
based on all the probesets utilized in our microarray anal-
ysis. Apparent separation between OTSCC and normal
groups was observed with a few outliers (Figure 1). Genes
showing statistically significant differences in expression
level were identified using RMA and a mixed-effects
model as described in the Materials and Methods section.
A signature gene set that consists of 35 genes was created
using stringent statistical criteria (fold change > 4, and
FDR values < 0.0001) (Table 1). Comprehensive lists of
genes showing statistically significant upregulations (fold
change > 2, and FDR values < 0.01) or downregulations in
expression in OTSCC were presented in Supplement Table
S1 [see additional file 1] and S2 [see additional file 2],
respectively.
In this study, we identified and validated several interest-
ing potential biomarkers for OTSCC diagnosis. One inter-
esting observation is that 5 members of the Matrix
Metalloproteinase (MMP) family (MMP1 MMP3, MMP9,
MMP10, and MMP12) are among the genes that most sig-
nificantly upregulated, which may contribute to the
aggressive nature of the OTSCC. MMPs are a large family
of proteinases which remodel extracellular matrix (ECM)
components and play a significant role in tumor develop-
ment, survival, invasion and metastasis [11-13]. Several
members of the MMP family have been considered to be
important biomarkers for diagnosis and prognosis as well
as potential therapeutic targets for many types of cancers,
including HNOSCC [14]. Our recent study suggested that
up regulation of the MMP9 gene is associated with
advanced OTSCC and has predictive value for the identi-
fication of lymph node metastasis [15]. Here, our data fur-
ther suggested that MMP9 is one of the biomarkers for the
detection of OTSCC. We also observed 2 chemokines (IL8
and CXCL1) to be among the most significantly upregu-
lated genes in OTSCC. The increase in the protein and
mRNA of IL8 gene has been suggested as a biomarker for
the early detection of oral cancer [16,17]. Our data pro-
vided independent validation for this biomarker at the
disease tissue level, and suggested that the increase of IL8
molecules (mRNA and protein) is due at least in part to
the increased expression of gene in the disease tissues.
CXCL1, also known as growth-regulated oncogene 1
(Gro-1), is vital for the survival, progression and invasion
of several cancer types [18,19], including oral cancer [20].
Our results here further confirmed the importance of
CXCL1 in the tumorgenesis of tongue cancer. Other inter-
Principle component analysis Figure 1
Principle component analysis. Global gene expression 
profiles on 53 OTSCC and 22 matching normal samples 
were obtained as described in Materials and Methods sec-
tion. Principle Component (PC) analysis was performed 
based on the expression profiles of samples. The first 3 PCs 
were plotted. Red: OTSCC, Blue: normal.BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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esting observations include the up-regulation of KRT17
(associated with invasion and proliferation) and down-
regulation of KRT4 (which is associated with squamous
cell differentiation), suggesting the potentially distinct
roles of KRT genes in tongue SCC development and pro-
gression. In addition to those identified biomarkers, our
results will also serve as a valuable reference data set for
future development and validation of biomarkers for
detection, diagnosis and prognosis of tongue cancer.
To test the utility of this 35-gene signature gene set for
classifying OTSCC and normal groups, average linkage
hierarchical clustering analysis was performed. As illus-
trated in Figure 2, our results demonstrated that this 35-
gene set provides classification power for OTSCC based
on gene expression analyses, which misclassified two
cases for each of two groups (a 95% overall accuracy rate).
Our analysis demonstrated that OTSCC can be identified
based on the gene expression signature. This finding
should provide a foundation for the creation of a specific
screen tool for OTSCC. One of the major factors account-
ing for the poor outcome of OTSCC patients is that a great
proportion of oral cancers are diagnosed at advanced
stages. Patients diagnosed at an early stage of the disease
typically have a better chance for cure and functional out-
come. Early detection of tongue cancer lesion will greatly
improve patient survival and the quality of life. Current
clinical diagnosis and histopathologic examinations are
usually based on biopsied material, which requires inva-
Table 1: Signature gene sets for OTSCC
Symbol Probe ID Gene Name Location
Upregulated genes in OTSCC
MMP1 204475_at matrix metalloproteinase 1 11q22.3
MMP10 205680_at matrix metalloproteinase 10 11q22.3
MMP3 205828_at matrix metalloproteinase 3 11q22.3
MMP12 204580_at matrix metallopeptidase 12 11q22.3
PTHLH 211756_at parathyroid hormone-like hormone 12p12.1-p11.2
INHBA 210511_s_at inhibin, beta A 7p15-p13
LAMC2 202267_at laminin, gamma 2 1q25-q31
IL8 202859_x_at interleukin 8 4q13-q21
KRT17 205157_s_at keratin 17 17q12-q21
COL1A2 202404_s_at collagen, type I, alpha 2 7q22.1
IFI6 204415_at interferon, alpha-inducible protein 6 1p35
ISG15 205483_s_at ISG15 ubiquitin-like modifier 1p36.33
PLAU 205479_s_at plasminogen activator, urokinase 10q24
GREM1 218468_s_at gremlin 1 15q13-q15
MMP9 203936_s_at matrix metallopeptidase 9 20q11.2-q13.1
IFI44 214453_s_at interferon-induced protein 44 1p31.1
CXCL1 204470_at chemokine (C-X-C motif) ligand 1 4q21
Downregulated genes in OTSCC
KRT4 213240_s_at keratin 4 12q12-q13
MAL 204777_s_at mal, T-cell differentiation protein 2cen-q13
CRNN 220090_at Cornulin 1q21
SCEL 206884_s_at Sciellin 13q22
CRISP3 207802_at cysteine-rich secretory protein 3 6p12.3
SPINK5 205185_at serine protease inhibitor, Kazal type 5 5q32
CLCA4 220026_at chloride channel, calcium activated, family member 4 1p31-p22
ADH1B 209612_s_at 209613_s_at alcohol dehydrogenase IB (class I), beta polypeptide 4q21-q23
P11 206605_at 26 serine protease 12q13.1
TGM3 206004_at transglutaminase 3 20q11.2
RHCG 219554_at Rhesus blood group, C glycoprotein 15q25
PPP1R3C 204284_at protein phosphatase 1, regulatory (inhibitor) subunit 3C 10q23-q24
CEACAM7 206199_at carcinoembryonic antigen-related cell adhesion molecule 7 19q13.2
HPGD 203914_x_at hydroxyprostaglandin dehydrogenase 15-(NAD) 4q34-q35
CFD 205382_s_at D component of complement (adipsin) 19p13.3
ABCA8 204719_at ATP-binding cassette, sub-family A (ABC1), member 8 17q24
CLU 222043_at Clusterin 8p21-p12
CYP3A5 214235_at cytochrome P450, family 3, subfamily A, polypeptide 5 7q21.1
* The complete lists of upregulated and downregulated transcripts in OTSCCs were presented in Supplement Table S1 and S2, respectively.BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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sive procedures and surgical techniques. The emerging
technology of saliva-based diagnosis may provide an
alternative strategy for early diagnosis and screening of the
subjects at risk [21]. The markers identified here may be
suitable for the saliva-based early diagnosis and screening
strategy [17,21]. Additional validation studies will be
needed to fully explore this possibility.
To gain a better understanding of the underlying molecu-
lar biological processes that dictate the observed expres-
sional pattern alterations in OTSCC development, the
Gene Ontology analysis was performed. It was carried out
using the GOstats package in the Bioconductor [22] and
Gene Ontology Consortium database [23], based on the
complete list of 365 differentially expressed transcripts
(Supplement Table S1 and S2). Among those 365 genes,
306 were mapped to ENTREZ genes. The gene universe in
the analysis consists of 13125 transcripts that were
mapped to ENTREZ genes. The Gene Ontology analysis
suggested a number of altered biological processes in
OTSCC. These include enhancement in phosphate trans-
port, collagen catabolism, I-kappaB kinase/NF-kappaB
signaling cascade, extracellular matrix organization and
biogenesis, chemotaxis, as well as suppression of superox-
ide release, hydrogen peroxide metabolism, cellular
response to hydrogen peroxide, keratinization, keratinoc-
yte differentiation in OTSCCs (Table 2). The complete
lists of enhanced and suppressed biological processes,
molecular functions and cellular components in OTSCCs
were presented in Supplement Table S3 [see additional
file 3] and S4 [see additional file 4], respectively.
Among the identified alteration in biological activities in
OTSCC, the most significantly enhanced are related to the
Classification of OTSCC and matching normal using global gene expression analysis Figure 2
Classification of OTSCC and matching normal using global gene expression analysis. A signature gene set of 35 
genes was created based on RMA analysis of the expression profiles on 53 OTSCC and 22 matching normal samples. Hierar-
chical clustering was performed based on this signature gene set. To removed the effect of baseline and scale in the color 
image, the data from every transcript was standardized (remove mean, divide by standard deviation) before plotting.BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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extracellular matrix remodeling (GO:0030574,
GO:0030198), I-kappaB kinase/NF-kappaB cascade
(GO:0043123) and chemotaxis (GO:0050921), which
are known to be related to tumorgenesis and progression
of the cancer. One interesting observation is the enhance-
ment in phosphate transport (GO:0006817) in OTSCC.
This may be related directly to the enhanced metabolic
activity and energy consumption rate in OTSCCs. It has
also been suggested that phosphate can act as a signaling
molecule on the extracellular signal-regulated kinase
(ERK1/2) [24] and adenylate cyclase/cAMP signaling
pathways [25], and ultimately affect cell growth. How-
ever, the precise role of enhanced phosphate transport in
tumorgenesis is largely unclear. The significantly sup-
pressed biological activities, such as superoxide release
(GO:0042554), hydrogen peroxide metabolism
(GO:0042743), and response to hydrogen peroxide
(GO:0042542) are all appeared to be related to the cellu-
lar redox state. The effects of redox state in malignancies
are somewhat contradictory. In theory, reducing the oxi-
dative stress may prevent DNA degeneration and therefore
prevent the development of cancer. However, doing so
may also offer increased growth potential to tumor cells
and protect them from excess of reactive oxygen species
(ROS), which would otherwise lead to apoptosis or necro-
sis. At the center of this apparent controversy is superoxide
dismutase 2 (SOD2), which has been considered as one of
the most important antioxidant enzymes. The role of
SODs in carcinogenesis has been widely studied but is still
rather ambiguous. While the majority of in vitro studies
have reported a protective role of SOD2 against tumor
progression in cancer cell lines [26-30], including oral
cancer cell lines [31], the in vivo studies indicate more
complicated roles. Increased SOD2 levels have been
observed from esophageal, gastric, brain astrocytic and
colorectal carcinomas, and often associated with metasta-
sis and poor prognosis [32-40]. The status of SOD2 in
breast cancer is not clear, with some studies showing an
increase [41], while others showing a decrease in SOD2
level [42]. Reduction in SOD2 level has been observed in
prostatic carcinomas [43,44]. Our microarray results indi-
cated a significant increase in expression of SOD2 gene
(probset: 215223_s_at; fold change = 2.37; p value =
0.00014; and probeset: 216841_s_at; fold change = 2.24;
p value = 0.000197) in OTSCC. These findings are in
agreement with the recent observation in oral cancer [45].
Additional studies will be needed to fully understand the
role(s) of redox state and SOD2 in OTSCC.
To visualize the changes in gene expression patterns in
relationship with the alteration of biological processes
and cellular functions in OTSCC, gene expression heat
maps for each identified GO entities were generated based
on the microarray results of 53 OTSCC and 22 normal
samples (Figure 3). Apparent differences in expression
patterns can be observed between OTSCC and normal
groups for all the altered GO entities. The summarized sta-
tistical values on differential expression for each individ-
ual gene of GO:0030574 (collagen catabolism) and
GO:0050921 (positive regulation of chemotaxis) are pre-
sented in Table 3. The complete expressional analysis for
all the altered biological processes identified in Table 2 is
presented in Supplement Table S5 [see additional file 5].
Among these differentially expressed genes, some have
potential value as diagnosis and prognosis markers, and
may be indicative of their respective biological pathways.
For example, IL8 is a prototypical chemokine (chemotac-
tic cytokine) and is known for its involvements in the pos-
itive regulation of chemotaxis (GO:0050921), which is
Table 2: Selected biological processes that altered in OTSCCs *
GO Name GO ID % Change ** p-value
Enhanced
Collagen catabolism GO:0030574 38.9 2.7 E-09
Positive regulation of chemotaxis GO:0050921 33.3 0.0029
Phosphate transport GO:0006817 21.7 1.5 E-12
Extracellular matrix organization and biogenesis GO:0030198 12.9 0.00089
Positive regulation of I-kappaB kinase/NF-kappaB cascade GO:0043123 8.8 0.00038
Suppressed
Superoxide release GO:0042554 40.0 0.0015
Keratinization GO:0031424 33.3 1.1 E-05
Hydrogen peroxide metabolism GO:0042743 25.0 0.0042
Response to hydrogen peroxide GO:0042542 22.2 0.0053
Keratinocyte differentiation GO:0030216 21.1 8.0 E-05
* The complete lists of enhanced and suppressed biological processes (BP), molecular functions (MF) and cellular components (CC) in OTSCCs 
were presented in Supplement Table S3 and S4, respectively.
** The percent of genes exhibiting expressional changes among all genes that constitutes a specific GO entity.BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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enhanced in tongue cancers as indicated by our Gene
Ontology analysis. IL8 has also been suggested to be a
potential biomarker for the early detection of oral cancer
[16,17]. The over-expression of the MMP9 gene has been
shown to be associated with progression of oral dysplasia
to cancer [14]. Our recent study suggested that over-
expression of the MMP9 gene is associated with advanced
OTSCC and has predictive value for OTSCC lymph node
metastasis [15]. The upregulation of MMP9 in OTSCC is
also involved in the enhanced collagen catabolism
(GO:0030574), as indicated by our Gene Ontology anal-
ysis. The qRT-PCR analyze were performed to validate the
expressional differences of the IL8 and MMP9 genes
between tongue SCCs and normal matching tissues. As
shown in Figure 4A and 4B, the differences of both IL8
and MMP9 mRNA levels are statistically significant (p <
.05) between OTSCC and normal tissues. The expression
of MMP9 and IL8 was further confirmed by immunohis-
Expression values of the genes constitute of the altered biological processes in OTSCC Figure 3
Expression values of the genes constitute of the altered biological processes in OTSCC. The altered biological 
processes in OTSCC were identified by Gene Ontology analysis (Table 2) as described in the Materials and Methods section. 
The expression values of the genes consisting of the altered biological processes were extracted from the RMA based expres-
sion index, and individual heat maps were generated for the identified altered biological processes in OTSCC. To removed the 
effect of baseline and scale in the color image, the data from every transcript was standardized (remove mean, divide by stand-
ard deviation) before plotting. To increase the contrast, values lower than the 10th percentile were replaced with the 10th per-
centile, and values higher than the 95th percentile were replaced with the 95th percentile.BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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tochemistry tests performed using monoclonal antibody
to IL8 and MMP9 on 10 OTSCC cases (Figure 4C and 4D).
Strong positive stained SCC cells were observed in 4 cases
for IL8 and 8 cases for MMP9. The observation of positive
staining of IL8 in OTSCC cells confirmed that SCC cells
are one of the major sources of IL8 production at the site
of oral cancer lesion.
Conclusion
The HNOSCCs are a diverse group of cancers, that develop
from many different anatomic sites and are associated
with different risk factors [1] and genetic characteristics
[2]. This is the first high-resolution genomic profiling
study to our knowledge that has focused on identifying
unique expression patterns for tongue cancer (OTSCC).
OTSCC is one of the most common types of HNOSCC,
and is significantly more aggressive than other forms of
HNOSCCs, with a propensity for rapid local invasion and
spread [6]. Recent epidemiological studies suggested that
the incidence of OTSCC is actually increasing in young
and middle age groups [3-5]. In this study, we utilized a
relatively large sample size (53 OTSCCs and 22 normal
matching samples), which enabled us to capture a precise
picture of the genome-wide expression pattern for this dis-
ease. It is possible that the genomic portrait of HNOSCC
originating from different anatomic sites may be different.
More studies will be needed to address this important
question.
In summary, we identified the unique expression pattern
for OTSCC. Several interesting candidate genes associated
with OTSCC were identified. The Gene Ontology analysis
indicated that several biological processes and cellular
functions are consistently altered in OTSCC. Our results
demonstrate the feasibility of utilizing biomarkers discov-
ered by global expression profiling analyses for the detec-
tion and diagnosis of OTSCC. In addition, we also
provided a valuable reference dataset for future identifica-
tion and validation of biomarkers for detection, diagnosis
and prognosis of OTSCC.
Methods
Patients
Microarray data were generated from 26 microdissected
OTSCC tissues and 12 matching normal tissue samples.
Three additional microarray datasets from 27 OTSCC
cases and 10 matching normal control tissues that pub-
lished previously were either downloaded from GEO
database (GSE2280, [46] and GSE3524, [47]) or
requested from the authors [7]. Clinical characterizations
of these patients are outlined in Table 4. The tumor stages
were determined according to the American Joint Com-
mittee on Cancer (AJCC) designated classification. This
study is approved by Institutional Review Boards at Uni-
versity of California at Los Angeles and at University of
Illinois at Chicago.
Tumor procurement, RNA extraction and microarray 
hybridization
The OTSCC tissues and their matching normal samples
were obtained for this study. These tissues were snap fro-
zen. Cancer tissues containing more than 80% tumor cells
based on haematoxylin and eosin (H&E) staining and
pathological examination were identified and selectively
microdissected by a trained pathologist. The total RNA
was isolated using RNeasy Mini kit (Qiagen), and quanti-
fied by the RiboGreen RNA Quantitation Reagent (Molec-
ular Probes). A total of 150–200 ng of purified total RNA
was amplified by a modified T7 RNA amplification proto-
col as described previously [15,17]. The Enzo BioArray
High Yield RNA Transcript Labeling System (Enzo) was
used for labeling the sample prior to hybridization. The
biotinylated cRNA (IVT product) was purified using the
RNeasy kit (Qiagen). The quantity and purity of the bioti-
nylated cRNA was determined by spectrophotometry and
an aliquot of the sample was checked by gel electrophore-
sis. The samples were hybridized to the Affymetrix
Human Genome U133 Plus 2.0 GeneChip arrays accord-
Table 3: Expression values of genes that constitute the collagen 
catabolism (GO:0030574) and positive regulation of chemotaxis 
(GO:0050921) processes in OTSCC.
GO term entrzID Gene 
Symbol
Fold change FDR level
GO:0030574
4312 MMP1 57.6 0
4313 MMP2 1.44 0.109
4314 MMP3 8.43 1.01E-08
4316 MMP7 2.83 0.0049
4317 MMP8 1.01 0.7963
4318 MMP9 4.08 5.85E-05
4319 MMP10 8.45 9.95E-06
4320 MMP11 2.02 0.00085
4322 MMP13 3.79 0.0007
4325 MMP16 0.93 0.1117
4327 MMP19 1.08 0.4404
5184 PEPD 0.92 0.4602
5645 PRSS2 0.76 0.0187
5653 KLK6 0.73 0.4218
5657 PRTN3 0.96 0.2656
9508 ADAMTS3 1.05 0.5858
9509 ADAMTS2 1.19 0.2451
56547 MMP26 0.94 0.2394
GO:0050921
9353 SLIT2 0.88 0.1700
566 AZU1 0.95 0.1643
3576 IL8 5.87 1.54E-06
6696 SPP1 3.23 0.0027
7422 VEGF 1.20 0.4614
7857 SCG2 1.00 0.9901BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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ing to the Affymetrix protocols. The arrays were scanned
with a GeneChip Scanner 3000. The scanned array images
were processed with GeneChip Operating software
(GCOS), and the CEL files were extracted for further anal-
ysis.
Array data analysis and gene ontology analysis
The CEL files from all datasets (newly generated array data
from 26 OTSCCs and 12 matching normals, and addi-
tional 27 OTSCCs and 10 normals from published studies
[7,46,47]) were imported into the statistical software R
2.4.1 [48] using Bioconductor [49]. The meta-analysis was
performed as described [50]. In brief, the Robust Multi-
Array Average (RMA) expression measures [51] were com-
puted after background correction and quantile normali-
zation for each microarray dataset. Then, expression
values of the overlapping probesets between U133A and
U133 Plus 2.0 arrays were extracted. Probeset-level quan-
tile normalization was performed across all samples to
make the effect sizes similar among the four datasets. To
visualize the overall expression patterns, we performed
Principal Component Analysis (PCA) after removing the
normal group mean vector separately from each of the
four datasets. Finally, for every probeset, a mixed effects
model was applied to identify differential expression. For
gene i in sample k of experiment j,
Elevated expressions of IL8 and MMP9 genes in OTSCC Figure 4
Elevated expressions of IL8 and MMP9 genes in OTSCC. The qRT-PCR tests were performed with primer sets specific 
for IL8 gene (A) and MMP9 gene (B) on 25 OTSCC cases and 12 normal matching samples. The p values (Wilcoxon test) were 
presented. Immunohistochemistry tests were performed using monoclonal antibody to IL8 and MMP9 and detected using per-
oxidase-antiperoxidase and diaminebenzadine (DAB) on 10 OTSCC cases. Positive stained SCC cells were observed in 4 cases 
for IL8 and 8 cases for MMP9. Representative images for IL8 (C) and MMP9 (D) were presented.
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Table 4: Clinical Characterization of the OTSCC Patients*
OTSCC (n = 53) Normal 
(n = 22)
Age Average 57 56
(Range) 32–82 37–78
Gender Male (%) 73.6 59.1
Female (%) 26.4 40.9
Anatomic Site Tongue (%) 100 100
Pathological T Stage Stage 4 (%) 56.6
Stage 3 (%) 7.5
Stage 2 (%) 22.6
Stage 1 (%) 13.2
Pathological N 
Stage
Stage 2 (%) 43.4
Stage 1 (%) 7.5
Stage 0 (%) 49.1
* The M stage data is not available.BMC Genomics 2008, 9:69 http://www.biomedcentral.com/1471-2164/9/69
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In the model, the random effect α ij is the laboratory effect,
and β i is the first-order cancer effect, which is our major
focus in the identification of cancer-associated genes.
After obtaining the estimates and the p-values of the βi's
of each probeset, we corrected the p-values for false dis-
covery rate (FDR) [52]. We selected genes at the FDR level
of 0.01, and with cancer effect size > 1 (> 2 fold change
between cancer and normal samples). Functional analysis
of the differentially expressed genes was carried out using
the GOstats package in Bioconductor [22] based on the
Gene Ontology Consortium database [23].
Quantitative RT-PCR(qRT-PCR)
The mRNA levels of interleukin-8 (IL8) and matrix metal-
loproteinases 9 (MMP9) in OTSCCs and normal tissues
were further validated using qRT-PCR as previously
described [15,17]. The RNA was converted to first strand
cDNA using MuLV reverse transcriptase (Applied Biosys-
tems) and the quantitative PCR was performed using iQ
SYBR Green Supermix (Bio-Rad) in a BIO-RAD iCycler iQ
real-time PCR detection system. The primer sets specific
for IL8 (Forward: 5'-GAGGGTTGTGGAGAAGTTTTTG-3',
Reverse: 5'-CTGGCATCTTCACTGATTCTTG-3') and for
MMP9 (Forward: 5'-GCACGACGTCTTCCAGTACC-3',
Reverse: 5'-TCAACTCACTCCGGGAACTC-3') were used.
All reactions were performed in triplicate. The melting
curve analyses were performed to ensure the specificity of
the qRT-PCR reactions. The data analysis was performed
using the 2-deltadelta Ct method described previously [53],
where beta-actin was used as reference gene. The qRT-PCR
based gene expression values between two groups were
compared by the nonparametric Wilcoxon test.
Immunohistochemistry
The expression of IL8 and MMP9 in OTSCCs were further
examined using immunohistochemistry tests as previ-
ously described [54]. In brief, the OTSCC tissues were
processed, embedded, and sectioned at 5 μm. Tissue sec-
tions were stained using monoclonal antibody to IL8
(MAB208) (R & D Systems) and MMP9 (ab51203)
(Abcam, Inc) and detected using peroxidase-antiperoxi-
dase and diaminebenzadine (DAB) with a Discovery XT
automated instrument (Ventana Medical Systems, Inc).
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